Potential of p38 inhibitors in the treatment of rheumatiod arthritis

Drug News and Perspectives

Volumn 13, Issue 8, 2000, Pages 488-497

  Foster, M L ^a   Halley, F ^a   Souness, J E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 FLUOROPHENYL) 5 (4 METHYLSULFINYLPHENYL) 3 (4 PYRIDYL)PYRROLE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (3 MORPHOLINOPROPYL)IMIDAZOLE; 5 (4 PYRIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 METHOXYPHENYL)IMIDAZO[2,1 B]THIAZOLE 1 OXIDE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; 6 AMINO 2 (4 FLUOROPHENYL) 4 METHOXY 3 (4 PYRIDYL) 1H PYRROLO[2,3 B]PYRIDINE; 6,7 DIHYDRO 2 [4 (METHYLSULFINYL)PHENYL] 3 (4 PYRIDYL) 5H PYRROLO[1,2 A]IMIDAZOLE; ANTIRHEUMATIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; SB 206718; SB 242235; STEROID; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; NONHUMAN; OSTEOPENIA; PALLIATIVE THERAPY; RAT; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT;

EID: 0034513614     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Histopathology of the rheumatoid joint
2. Molecular and cellular interactions in the rheumatoid synovium
3. Arthritogenic actions of recombinant of IL-1 and TNFa in the rabbit
4. The role of current strategies in the future treatment of rheumatoid arthritis
5. Corticosteroids in the treatment of rheumatologic disease
6. Future trends in the treatment of rheumatoid arthritis: Cytokine targets
7. Kinase targets in inflammation
8. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases
9. p38 MAPK signalling cascades in inflammatory disease
10. The search for physiological substrates of MAP and SAP kinases in mammalian cells
11. Novel homologues of CSB-P/p38 MAP kinase: Activation, substrate specificity and sensitivity to inhibition by pyridinylimidazoles
12. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms
13. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors
14. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
15. Pyridinylimidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site
16. p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
17. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding
18. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase
19. New inhibitors of p38 kinase
20. Structural basis of inhibitor selecrivity in MAP kinases
21. Molecular basis for p38 protein kinase inhibitor specificity
22. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
23. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
24. SB-203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes
25. Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSB-P kinase
26. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase
27. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis
28. Impaired on/off regulation of TNF-alpha biosynthesis in mice lacking TNF-alpha AU-rich elements: Implications for joint and gut-associated immunopathologies
29. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
30. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
31. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
32. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
33. Selective inhibition of p38 mitogen activated kinase reduces brain injury and neurological deficits in rat focal stroke models
34. 2,4,5-Triarylimidazole inhibitors of IL-1beta biosynthesis
35. p38 mitogen-activated protein kinase as a target for drug discovery
36. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated disease
37. Inhibitors of p38 kinase
38. Structural basis of inhibitor selectivity in MAP kinases
39. 1-Substituted 4-aryl-5-pyridinyl-imidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
40. Pyrroles and other heterocycles as inhibitors of p38 kinase
41. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
42. RJW67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
43. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase
44. Potent inhibitors of the MAP kinase p38
45. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-IH-pyrrolo[2,3-b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor
46. New low-density lipoprotein receptor upregulators acting via a novel mechanism
47. The discovery of RPR 200765A: A novel inhibitor of p38 MAP kinase
48. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic activity
49. Acyl-CoA: Cholesterol O-acyltransferase (ACAT) inhibitors. 2.2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT
50. Anatomy of TNFa protein expression in synovialjoint tissues from a rat model of rheumatoid arthritis
51. Bacterial cell-wall induced arthritis
52. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443
53. FK506 in experimental renal allografts in dogs and primates
54. In vivo activity of leflunomide: Pharmacokinetic analyses and mechanism of immunosuppression
55. SK&F 105809 initiates and promotes hepatic foci in rats
56. Evaluation of SK&F 86002, SK&F 105809 and SB 203580 in the Pro-Tox assay
57. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis
58. Pyrimidinylimidazole inhibitors of CSB-P/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
59. Genotoxicity, carcinogenicity and acid-suppressing medications
60. Induction of cytochrome P-450 1A1 by omeprazole in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naph-thoflavone